Treatment outcome of early-stage NK/T-cell lymphoma using combined RT and CT in selected studies
| Treatment . | No. patients . | ORR, % . | CR, % . | OS . | PFS . | Reference . |
|---|---|---|---|---|---|---|
| RT → CHOP | 172 | 93.3 | 82.2 | 3 y: ∼80% | NA | 1 |
| RT → l-asparaginase/gem-based CT | 37 | 93.3 | 82.2 | 3 y: ∼80% | NA | |
| CHOP → RT | 523 | 61.3 | 25.1 | 3 y: ∼70% | NA | |
| l-asparaginase/gem-based CT → RT | 118 | 77.9 | 31.6 | 3 y: ∼70% | NA | |
| SMILE + sandwich RT | 29 | 86 | 69 | NA | NA | 7 |
| LVP + sandwich RT | 26 | 92 | 42 | 2 y: 89% | 2 y: 81% | 8 |
| GELOX + sandwich RT | 27 | 93 | 56 | 2 y: 86% | 2 y: 86% | 9 |
| Treatment . | No. patients . | ORR, % . | CR, % . | OS . | PFS . | Reference . |
|---|---|---|---|---|---|---|
| RT → CHOP | 172 | 93.3 | 82.2 | 3 y: ∼80% | NA | 1 |
| RT → l-asparaginase/gem-based CT | 37 | 93.3 | 82.2 | 3 y: ∼80% | NA | |
| CHOP → RT | 523 | 61.3 | 25.1 | 3 y: ∼70% | NA | |
| l-asparaginase/gem-based CT → RT | 118 | 77.9 | 31.6 | 3 y: ∼70% | NA | |
| SMILE + sandwich RT | 29 | 86 | 69 | NA | NA | 7 |
| LVP + sandwich RT | 26 | 92 | 42 | 2 y: 89% | 2 y: 81% | 8 |
| GELOX + sandwich RT | 27 | 93 | 56 | 2 y: 86% | 2 y: 86% | 9 |
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisolone; CR, complete response rate after initial RT or CT; GELOX, gemcitabine, l-asparaginase, and oxaliplatin; gem, gemcitabine; LVP, l-asparaginase, vincristine, and prednisolone; ORR: overall response rate after initial RT or CT; OS, overall survival; PFS, progression-free survival; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide.